Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing